{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:36:29Z","timestamp":1769740589348,"version":"3.49.0"},"reference-count":13,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,9]]},"abstract":" PURPOSE: To evaluate the efficacy and toxicity of gemcitabine (2\u2032,2\u2032-difluorodeoxycytidine) plus cisplatin in previously untreated patients with advanced transitional-cell carcinoma. <\/jats:p> PATIENTS AND METHODS: Thirty-one patients with measurable advanced transitional-cell carcinoma who had received no prior chemotherapy for metastatic disease were scheduled to receive gemcitabine 1,000 mg\/m2<\/jats:sup> intravenously over 30 minutes on days 1, 8, and 15 and cisplatin 70 mg\/m2<\/jats:sup> over 1 hour on day 2 of a 28-day cycle. Prior adjuvant or neoadjuvant therapy for locally advanced disease was allowed if this was completed more than 1 year before study entry. <\/jats:p> RESULTS: There were six complete responses and 10 partial responses in 28 assessable patients, for anoverall response rate of 16 of 28 (57%). The response rate on an intent-to-treat basis was 16 of 31 patients (52%). The median survival is 13.2 months, with 18 patients still alive at this time. Toxicity was primarily hematologic, with 12 of 31 patients (39%) having \u2265 grade 3 granulocytopenia and 17 of 31 (55%) having \u2265 grade 3 thrombocytopenia. Two patients had febrile neutropenia. All patients required a dose modification of gemcitabine at some point in their therapy; the primary reason was thrombocytopenia and\/or neutropenia. <\/jats:p> CONCLUSION: Gemcitabine plus cisplatin is an active regimen for the treatment of urothelial cancer. <\/jats:p>","DOI":"10.1200\/jco.1999.17.9.2876","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:05:40Z","timestamp":1487916340000},"page":"2876-2876","source":"Crossref","is-referenced-by-count":182,"title":["Gemcitabine Plus Cisplatin, an Active Regimen in Advanced Urothelial Cancer: A Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group"],"prefix":"10.1200","volume":"17","author":[{"given":"Malcolm J.","family":"Moore","sequence":"first","affiliation":[{"name":"From the BC Cancer Agency, Vancouver, British Columbia; Princess Margaret Hospital, Toronto; London Regional Cancer Centre, London; Ottawa Regional Cancer Centre, Ottawa; and the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric W.","family":"Winquist","sequence":"additional","affiliation":[{"name":"From the BC Cancer Agency, Vancouver, British Columbia; Princess Margaret Hospital, Toronto; London Regional Cancer Centre, London; Ottawa Regional Cancer Centre, Ottawa; and the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevin","family":"Murray","sequence":"additional","affiliation":[{"name":"From the BC Cancer Agency, Vancouver, British Columbia; Princess Margaret Hospital, Toronto; London Regional Cancer Centre, London; Ottawa Regional Cancer Centre, Ottawa; and the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian F.","family":"Tannock","sequence":"additional","affiliation":[{"name":"From the BC Cancer Agency, Vancouver, British Columbia; Princess Margaret Hospital, Toronto; London Regional Cancer Centre, London; Ottawa Regional Cancer Centre, Ottawa; and the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Huan","sequence":"additional","affiliation":[{"name":"From the BC Cancer Agency, Vancouver, British Columbia; Princess Margaret Hospital, Toronto; London Regional Cancer Centre, London; Ottawa Regional Cancer Centre, Ottawa; and the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Bennett","sequence":"additional","affiliation":[{"name":"From the BC Cancer Agency, Vancouver, British Columbia; Princess Margaret Hospital, Toronto; London Regional Cancer Centre, London; Ottawa Regional Cancer Centre, Ottawa; and the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Walsh","sequence":"additional","affiliation":[{"name":"From the BC Cancer Agency, Vancouver, British Columbia; Princess Margaret Hospital, Toronto; London Regional Cancer Centre, London; Ottawa Regional Cancer Centre, Ottawa; and the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Seymour","sequence":"additional","affiliation":[{"name":"From the BC Cancer Agency, Vancouver, British Columbia; Princess Margaret Hospital, Toronto; London Regional Cancer Centre, London; Ottawa Regional Cancer Centre, Ottawa; and the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-2876","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7"},{"key":"R2-2876","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1066"},{"key":"R3-2876","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2564"},{"key":"R5-2876","unstructured":"Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine. Cancer Res 50:4417,1990-4422,"},{"key":"R6-2876","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058775"},{"key":"R7-2876","unstructured":"DeLena M, Gridelli C, Lorusso V, et al: Gemcitabine activity in resistant stage IV bladder cancer. Proc Am Soc Clin Oncol 15:246,1996, (abstr)"},{"key":"R8-2876","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.12.3441"},{"key":"R9-2876","doi-asserted-by":"crossref","unstructured":"Stadler WM, Kuzel T, Roth B, et al: Phase II trial of gemcitabine in previously untreated patients with urothelial cancer. J Clin Oncol 14:3394,1997-3398,","DOI":"10.1200\/JCO.1997.15.11.3394"},{"key":"R10-2876","unstructured":"Crino L, Scaglotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in non-small cell lung cancer: A phase II study. Proc Am Soc Clin Oncol 14:1066,1995,"},{"key":"R13-2876","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2264"},{"key":"R14-2876","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2271"},{"key":"R15-2876","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1844"},{"key":"R16-2876","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2722"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.9.2876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:29:09Z","timestamp":1653514149000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.9.2876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1999,9]]}},"alternative-id":["10.1200\/JCO.1999.17.9.2876"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.9.2876","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,9]]}}}